Biovie SUNRISE-PD: A Study of NE3107 in Early Parkinson’s About the study? The goal of this clinical trial is to learn if bezisterim can treat movement symptoms of Parkinson’s disease in patients that are 45 to 80 years old, in generally good physical and mental health, and are nearing the need for treatment to relieve […]
Biovie SUNRISE-PD: A Study of NE3107 in Early Parkinson’s Read More »
REVITALYZ: Safety and Efficacy of FT218 in Idiopathic Hypersomnia About the study? This is a double-blind, placebo-controlled study of the efficacy and safety of FT218. FT218 drug product is a once-nightly formulation of sodium oxybate for extended-release oral suspension. The study will enroll subjects who are diagnosed with idiopathic hypersomnia. Subjects will be eligible to
REVITALYZ: Safety and Efficacy of FT218 in Idiopathic Hypersomnia Read More »
Praxis RADIANT/POWER-1/Open-label Extension About the study? The Praxis studies are investigating how well vormatrigine works for treating focal onset seizures compared with placebo, as well as its safety and side effects compared with placebo. Vormatrigine is a new investigational medicine that is taken once a day and is currently being studied to see if it
Praxis RADIANT/POWER-1/Open-label Extension Read More »
COMPASS PATHWAYS COMP-006 About the phase 2b trial: This randomised controlled phase 2b study of investigational psilocybin treatment in treatment-resistant depression is the largest psilocybin treatment clinical trial ever conducted, with 233 patients across 22 sites in 10 countries across Europe and North America. This trial assessed the safety and efficacy of COMP360 psilocybin treatment in three
COMPASS PATHWAYS COMP-006 Read More »
ArgenX Empassion The Empassion study is designed to assess how safe and effective an investigational study drug, empasiprubart, is compared to intravenous immunoglobulin (IVIg) as a possible treatment for adults living with multifocal motor neuropathy (MMN). The clinical study is looking to enroll up to 100 participants across the world. Enrolled participants will be asked
EVIDERA EVA-38569-03 This is a cognitive interview study to evaluate Phase 2 Trial Anchors in Patients with Parkinson’s Disease. What to Expect This study involves in-depth interviews with adults who have been diagnosed with PD who meet specific criteria. For more information, contact Heather Macnamara at hmacnamara@dentinstitute.com or 716-819-4117
EVIDERA EVA-38569-03 Read More »
INDIVIOR INDV-6000-406 This study will provide the opportunity to generate data on the long-term use of SUBLOCADE under real-world conditions, and to observe enduring changes in lifestyle, health, and sociodemographic factors that are part of the recovery process. Inclusion Criteria: At least 18 years of age, has initiated treatment with SUBLOCADE within the last 3
INDIVIOR INDV-6000-406 Read More »
JAZZ PATAGONIA (Parkinson’s Disease) This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy and safety of suvecaltamide for the treatment of moderate to severe residual tremor in adult participants with Parkinson’s disease (PD). The target population represents participants who have tremor that is not adequately controlled by PD
ACADIA RADIANT (Alzheimer’s Disease Psychosis) In this study, researchers will evaluate ACP-204 in patients with Alzheimer’s Disease Psychosis. Inclusion Criteria: 50 years to 95 years of age Meets clinical criteria for possible or probable Alzheimer’s Disease Psychotic symptoms (hallucinations or delusions) for at least 2 months Availability of a designated study partner/caregiver What to Expect
SUVEN CTP3S1502HT6 (Alzheimer’s Disease with Agitation) This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer’s type. Inclusion Criteria: 50 years to 9o years Alzheimer’s Dementia (full criteria in link below) What to Expect Study
SUVEN CTP3S1502HT6 Read More »
